Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

12+ years of clinical experience in university hospitals in Germany and Spain.
International education: Ukraine – Germany – Spain.
Member of the German Society of Surgeons (BDC).
Certified in radiological diagnostics and robotic surgery.
Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.

How to use ALBUPLAN 50 G/L SOLUTION FOR INFUSION

Introduction

Package Leaflet: Information for the User

Albuplan 50 g/l, Solution for Infusion

Human Albumin

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

Keep this leaflet, you may need to read it again.
If you have any further questions, ask your doctor, pharmacist, or nurse.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the Package Leaflet

What is Albuplan 50 g/l and what is it used for
What you need to know before you use Albuplan 50 g/l
How to use Albuplan 50 g/l
Possible side effects
Storage of Albuplan 50 g/l
Contents of the pack and further information

1. What is Albuplan 50 g/l and what is it used for

Albuplan 50 g/l is presented as a solution for intravenous infusion containing proteins obtained from human plasma (plasma proteins), which is the liquid part of the blood. Each vial contains a solution with 50 g of plasma proteins/l, of which at least 95% is human albumin.

This medicine belongs to the group of medicines called plasma substitutes and plasma protein fractions.

Albuplan 50 g/l is used to restore and maintain circulating blood volume when a volume deficit has been demonstrated and the use of a colloid is considered appropriate.

If you have any doubts about the use of Albuplan 50 g/l, consult your doctor.

2. What you need to know before you use Albuplan 50 g/l

Do not use Albuplan 50 g/l

If you are allergic (hypersensitive) to the active substance or any of the other components of this medicine (listed in section 6) (see “Important information about some of the components of Albuplan 50 g/l” at the end of this section).

Be careful with Albuplan 50 g/l

If you have a special risk due to an increase in blood volume, for example, in cases of severe heart disease, arterial hypertension, dilated veins in the esophagus, fluid in the lungs, coagulation disorders, severe decrease in red blood cells or absence of urine.
When there are signs of increased blood volume (headache, respiratory disorder, jugular vein congestion) or increased blood pressure. The infusion should be stopped immediately.
When there are signs of an allergic reaction. The infusion should be stopped immediately.
When used in patients with severe brain injury due to trauma.

Information about transmission of infectious agents

When medicines derived from human plasma or blood are administered, certain measures are taken to prevent the transmission of infections to patients. Such measures include:

careful selection of donors, to exclude those who are at risk of being carriers of infectious diseases,
analysis of specific infection markers in individual donations and in plasma pools,
the inclusion of stages in the manufacturing process to eliminate/inactivate viruses.

Despite this, when medicines derived from human blood or plasma are administered, the possibility of transmitting infectious agents cannot be completely excluded. This also applies to emerging or unknown viruses or other types of infections.

No cases of viral infections have been reported with albumin manufactured according to the specifications and processes established in the European Pharmacopoeia.

It is highly recommended that each time healthcare personnel administer a dose of Albuplan 50 g/l, they record the name of the medicine and batch number administered in order to maintain a record of the batches used.

Use of Albuplan 50 g/l with other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines, including those obtained without a prescription.

No specific complications of human albumin with other medicines are known.

Pregnancy and breastfeeding

Consult your doctor or pharmacist before using any medicine.

Tell your doctor if you are pregnant or breastfeeding. Your doctor will decide if Albuplan 50 g/l can be used during pregnancy and breastfeeding.

Driving and using machines

No effects on the ability to drive or use machines have been observed.

Important information about some of the components of Albuplan 50 g/l

This medicine contains 333.5 mg of sodium (main component of table/cooking salt) in each 100 ml vial, 833.8 mg of sodium in each 250 ml vial, and 1667.5 mg of sodium in each 500 ml vial. This is equivalent to 16.7%, 41.7%, and 83.4%, respectively, of the maximum daily sodium intake recommended for an adult. However, depending on the required dose, it is possible that the patient may receive more than 1 vial.

This medicine contains less than 39 mg (1 mmol) of potassium per vial, so it is considered essentially "potassium-free".

3. How to use Albuplan 50 g/l

Albuplan 50 g/l is a hospital medicine, so it will be administered to you in a hospital by the corresponding healthcare personnel.

Your doctor will decide, based on your particular condition, the amount of product to be administered, the speed at which it will be administered, how often, and the duration of your treatment with Albuplan 50 g/l.

If you use more Albuplan 50 g/l than you should

If you have been administered more Albuplan 50 g/l than you should, consult your doctor or pharmacist immediately.

In case of overdose or accidental administration, consult the Toxicology Information Service. Phone: 91 562 04 20.

If you forget to use Albuplan 50 g/l

Consult your doctor immediately and follow their instructions.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Mild reactions such as flushing, skin rash, fever, nausea may occur. Such reactions are rare.

Very rarely, severe allergic reactions (anaphylactic shock) may occur.

For information on viral safety, see section 2.

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Albuplan 50 g/l

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP.

Do not store above 25°C. Do not freeze.

Keep the vial in the outer packaging to protect it from light.

The solution should be clear or slightly opalescent. Do not use this medicine if you notice that the solution is cloudy or has formed a deposit.

Once the pack is opened, the contents should be used immediately.

Disposal of unused medicine and all materials that have come into contact with it should be done in accordance with local regulations. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and further information

Composition of Albuplan 50 g/l

The active substance is human albumin. One milliliter of Albuplan 50 g/l contains 50 mg of plasma proteins, of which at least 95% is human albumin.

The other components are sodium chloride, sodium caprylate, sodium N-acetyltryptophanate, and water for injections.

See section 2 "Important information about some of the components of Albuplan 50 g/l" for additional information about the components.

Appearance of the product and pack contents

Albuplan 50 g/l is a solution for infusion. The solution is clear, slightly viscous, almost colorless, yellow, amber, or green.

Albuplan 50 g/l is presented in vials containing 100 ml, 250 ml, or 500 ml of product.

Pack sizes: 1 vial

Marketing authorization holder and manufacturer

Instituto Grifols, S.A.

Can Guasc, 2 - Parets del Vallès

08150 Barcelona - SPAIN

Date of last revision of this leaflet:June 2019

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.es/

This information is intended only for healthcare professionals:

Albuplan 50 g/l should be administered intravenously, by infusing the contents of the pack directly.

Human albumin should not be mixed with other medicines, whole blood, or red blood cell concentrates.

The solutions should be clear or slightly opalescent. Cloudy solutions or those with sediment should not be used, as this may indicate that the protein is unstable or the solution has been contaminated. Once the pack is opened, its contents should be used immediately.

The infusion should be carried out intravenously, using a single-use, sterile, and apyrogenic infusion set. Before inserting the infusion set into the stopper, it should be disinfected with a suitable antiseptic. Once the infusion set is connected to the vial, the contents should be infused immediately.

The infusion rate should be adjusted to the specific circumstances of each case and to the indication. During plasma exchange, the infusion rate should be adjusted to the exchange rate. If the dose and infusion rate are not adjusted to the patient's circulatory situation, hypervolemia may occur. In the event of the first clinical signs of circulatory overload (headache, dyspnea, jugular venous congestion), increased blood pressure, or increased venous pressure and pulmonary edema, the infusion should be interrupted.

If large volumes are administered, the product should be brought to room or body temperature before use.

When albumin is administered, the patient's electrolyte balance should be monitored and, if necessary, measures should be taken to restore or maintain it.

Adequate replacement of other blood components (coagulation factors, electrolytes, platelets, and red blood cells) should be ensured.

Unused solutions should be disposed of properly.

ALBUPLAN 50 G/L SOLUTION FOR INFUSION

Yevgen Yakovenko

Nuno Tavares Lopes

Yevgen Yakovenko

Nuno Tavares Lopes